Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
Zavedos 5 mg Capsules.
| Pharmaceutical Form |
|---|
|
Opaque red cap and body, self-locking, hard gelatin capsules, size no. 4, containing an orange powder. |
Idarubicin Hydrochloride 5.0 mg HSE.
| Active Ingredient | Description | |
|---|---|---|
| Idarubicin |
Idarubicin is a DNA intercalating anthracycline which interacts with the enzyme topoisomerase II and has an inhibitory effect on nucleic acid synthesis. Idarubicin has been shown to have a higher potency with respect to daunorubicin and to be an effective agent against murine leukaemia and lymphomas both by i.v. and oral routes. |
| List of Excipients |
|---|
|
Microcrystalline cellulose Ph. Eur. Capsule shell: Red iron oxide (E172) FP Printing ink: Shellac |
Type III amber glass bottles closed with an aluminium screw cap with a polyethylene gasket and a polyethylene cover cap. Aluminium/aluminium strips.
Pack size: 1.
Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
PL 00057/1064
10th May 2002
| Drug | Countries | |
|---|---|---|
| ZAVEDOS | Austria, Australia, Brazil, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Lithuania, Malta, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
